Clinical trials: Insulin Therapy
Diabetes, Diabetes Mellitus, Type 2
An Observational Study of Insulin Aspart and, if Necessary, Insulin Levemir (FlexPen®) in the Evening or at Bedtime
This study is conducted in Europe. The aim of this study is investigate the potential of a supplementary insulin therapy regimen (SIT) as intensification for insufficiently controlled patients with type 2 diabetes in a normal…
- Trial name
- NCT01487421
- Testing
- insulin aspart, insulin detemir
- Where
- Germany
- Volunteers
- 2,134 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Hybrid Closed Loop System for Patients on Multiple Daily Insulin Injections
The objective of this study is to assess structured group education onboarding protocol of the 670 G Hybrid Closed Loop (HCL) systems in achieving glucose control of patients on Multiple Daily Insulin Injections (MDI).
- Trial name
- NCT04145804
- Testing
- Medtronic Minimed 670G insulin pump
- Where
- Qatar
- Volunteers
- 40 people
- Sponsor
- Hamad Medical Corporation
Diabetes Mellitus, Type 2
Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy
This study enrolled participants with inadequately controlled type 2 diabetes mellitus (T2DM) despite non-insulin antidiabetic therapy in addition to diet and exercise, and would have benefited from additional control of blood…
- Trial name
- NCT01163721
- Testing
- Ranolazine
- Where
- 9 sites in United States
- Volunteers
- 80 people
- Sponsor
- Gilead Sciences
Diabetes Mellitus, Type 2
A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to compare the efficacy and safety of a new basal insulin, insulin peglispro, to insulin glargine in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02106364
- Testing
- Insulin Peglispro, Insulin Glargine
- Where
- 10 sites in United States
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
This study aims at describing the glucose level by automated glucose sensors and correlating it with insulin delivery and meals over 14 days in insulin-requiring T2D patients living in real-life conditions.
- Trial name
- CLOSE (NCT03436212)
- Testing
- Continuous Glucose Monitoring (CGM)
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Air Liquide Santé International
Type 1 Diabetes Mellitus
VV-14299 and VV-14300 for the Treatment of Type 1 Diabetes
This study is testing VV-14299 and VV-14300 or VV-14300 alone in adults with long-standing type 1 diabetes (T1D) whose blood sugar is not well controlled despite using an automated insulin delivery (AID) system.
- Trial name
- PROGRESS (NCT07829302)
- Testing
- VV-14300, VV-14299
- Where
- Australia
- Volunteers
- 29 people
- Sponsor
- Kriya Therapeutics, Inc.
Diabetes, Diabetes Mellitus, Type 2
Observational Study in Type 2 Diabetes Treated by an Intensive Insulin Treatment (ICT) Containing Once Daily Levemir® (Insulin Detemir)
This study is conducted in Europe. The aim of this observational study is to gain practical experience with once-daily Levemir administration in type 2 diabetes patients who were previously treated with Insulatard®, Humulin® N…
- Trial name
- LEONCET2 (NCT00657930)
- Testing
- insulin detemir
- Where
- Hungary
- Volunteers
- 2,289 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Insulin Glargine in Type 2 Diabetic Patients
Primary: To investigate the efficacy of insulin glargine (in terms of change in A1c from baseline to endpoint A1c < 7%) Secondary: To investigate the safety of insulin glargine (in terms of hypoglycaemia, including symptomatic…
- Trial name
- TARGET (NCT00347100)
- Testing
- Insulin Glargine, Glyburide, Glyclazide
- Where
- China
- Volunteers
- 387 people
- Sponsor
- Sanofi
Healthy Volunteers
An Insulin Sensitivity Study in Healthy Subjects
This study will characterize insulin sensitivity in response to treatment with ALKS 3831, olanzapine, and placebo.
- Trial name
- NCT02922426
- Testing
- ALKS 3831, Olanzapine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Alkermes, Inc.
Type 1 Diabetes Mellitus
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.
- Trial name
- DEPICT 2 (NCT02460978)
- Testing
- Dapagliflozin
- Where
- 136 sites in United States, Argentina and 11 more
- Volunteers
- 815 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this clinical trial is to compare the 24-hour pharmacodynamics/ pharmacokinetics of biphasic insulin aspart 30 (BiAsp 30) thrice daily treatment with that of a basal-bolus treatment…
- Trial name
- NCT00824668
- Testing
- biphasic insulin aspart 30, insulin glargine, insulin glulisine
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Cardiometabolic Syndrome
Establishing Clinical Utility Evidence for Chronic Disease Management Testing
This is a national-level research study of primary care physicians. The purpose of this study is to assess the clinical evaluation and management (drug, procedures, counseling and other) of a subset of common patient care…
- Trial name
- NCT05192590
- Testing
- Educational Materials and Chronic Disease Management Test (CDMT)
- Where
- United States
- Volunteers
- 247 people
- Sponsor
- Qure Healthcare, LLC
Diabetes, Diabetes Mellitus, Type 2
Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin
This trial is conducted in Asia, Europe, Oceania and South America. The aim of this clinical trial is to generate data demonstrating how to intensify diabetes treatment using BIAsp 30 (biphasic insulin aspart 30) by adding or…
- Trial name
- SIT2MIX (NCT01519674)
- Testing
- biphasic insulin aspart 30, sitagliptin, metformin
- Where
- 69 sites in Argentina, Australia and 8 more
- Volunteers
- 582 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 1 Diabetes Mellitus.
To determine, in subjects with Type 1 Diabetes Mellitus: 1. Whether glycemic control can be achieved at least as effectively with an insulin regimen involving pre-meal inhaled insulin plus a single bedtime Ultralente injection as…
- Trial name
- NCT00424437
- Testing
- Inhaled human insulin
- Where
- 36 sites in United States, Canada
- Volunteers
- 320 people
- Sponsor
- Pfizer
Diabetes, Diabetes Mellitus, Type 2
Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin
The study is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control in patients using a modern insulin: NovoRapid®, NovoMix® 30 or Levemir® for the treatment type 2 diabetes.
- Trial name
- COMMIT (NCT00676741)
- Testing
- insulin aspart, biphasic insulin aspart 30, insulin detemir
- Where
- Slovakia
- Volunteers
- 3,809 people
- Sponsor
- Novo Nordisk A/S
Metabolic Syndrome X
ROMEO (Rosuvastatin in Metabolic syndrOme)
The primary objective of this study is to compare the effect of rosuvastatin 10mg with atorvastatin 10mg after 6 weeks of treatment in the ratio of ApoB/ApoA1 in subjects with metabolic syndrome.
- Trial name
- NCT00395486
- Testing
- Rosuvastatin, Atorvastatin
- Where
- 3 sites in South Korea
- Volunteers
- 258 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Treated With Insulin
Study to Evaluate the Safety and Efficacy of Oral Insulin Formulation in Type 2 Diabetes Mellitus Subjects
The aim of the study was to compare the pharmacodynamic properties of different doses of regular human insulin administered in capsule form twice daily in a randomised twelve-week open-label trial.
- Trial name
- NCT06473662
- Testing
- Oral insulin
- Where
- United Kingdom
- Volunteers
- 153 people
- Sponsor
- Roger New
Pharmacokinetics and Pharmacodynamics
Comparison of the Pharmacokinetic (PK) and Pharmacodynamic (PD) Biosimilarity of Insulin Aspart 30 Injections After Single-Dose Subcutaneous Administration to Healthy Volunteers
The present study is designed to compare the pharmacokinetic, pharmacodynamic and safety characteristics of UBLIN 30® (test product) and NovoMix®30 (reference product) in healthy male participants.
- Trial name
- NCT07875803
- Testing
- Insulin Aspart 30 Injection (UBLIN 30®)), Insulin Aspart 30 Injection ( NovoMix®30)
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Zhuhai United Laboratories Co., Ltd.
Metabolic Syndrome
The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome
This study evaluated safety, tolerability and efficacy of Fluvastatin XL® -extended release (80 mg once daily) in patients with metabolic syndrome
- Trial name
- NCT00664742
- Testing
- Fluvastatin XL®
- Where
- Turkey (Türkiye)
- Volunteers
- 614 people
- Sponsor
- Novartis